Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
Recruiting · NCT05096715 · Registry updated 2026-02-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | Unresectable Hepatocellular Carcinoma | Recruiting | Phase 1 | 2026-02-18 | NCT05096715 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Massachusetts General Hospital | 758 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |